We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $931M
1-Year Est. Return 41.63%
This Fund
S&P 500
This Quarter Est. Return
-7.99%
1 Year Est. Return
+41.63%
3 Year Est. Return
+181.18%
5 Year Est. Return
+113.34%
10 Year Est. Return
+1,823.73%
AUM
$3.84B
AUM Growth
-$861M
Cap. Flow
-$395M
Cap. Flow %
-10.28%
Top 10 Hldgs %
67.4%
Holding
122
New
18
Increased
22
Reduced
23
Closed
17
Avg Time Held Equity + Options
4.9 quarters
Top 10 Avg Time Held Equity + Options
5.6 quarters
Top 20 Avg Time Held Equity + Options
4.8 quarters
Avg Time Held Equity only
5.3 quarters
Top 10 Avg Time Held Equity only
6.2 quarters
Top 20 Avg Time Held Equity only
7.4 quarters

Top Buys

Rank Stock Value
1
RUBY
Rubius Therapeutics, Inc
RUBY
+$66.5M
2
FOLD icon
Amicus Therapeutics
FOLD
+$15.4M
3
NIO icon
NIO
NIO
+$12.4M
4
BABA icon
Alibaba
BABA
+$11.5M
5
ANAB icon
AnaptysBio
ANAB
+$8.3M

Top Sells

Rank Stock Value
1
WW icon
WW International
WW
+$487M
2
BPMC icon
Blueprint Medicines
BPMC
+$13.9M
3
ONC icon
BeOne Medicines Ltd
ONC
+$12.6M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$9.04M
5
IMUX icon
Immunic
IMUX
+$6.85M

Sector Composition

Rank Sector Weight
1 Healthcare 46.31%
2 Consumer Discretionary 28.3%
3 Miscellaneous 25.15%
4 Technology 0.24%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
MRNS icon
76
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$5M 0.13%
125,000
– –
2017 Q4
3 quarters
WHWK icon
77
Whitehawk Therapeutics
WHWK
$201M
$4.82M 0.13%
103,893
– –
2018 Q2
1 quarter
CRSP icon
78
CRISPR Therapeutics
CRSP
$5.16B
$4.43M 0.12%
100,000
+50,000
+100% +$2.62M
2017 Q4
3 quarters
AKBA icon
79
Akebia Therapeutics
AKBA
$222M
$4.19M 0.11%
475,000
– –
2018 Q1
2 quarters
RCUS icon
80
Arcus Biosciences
RCUS
$3.11B
$4.18M 0.11%
300,000
– –
2018 Q1
2 quarters
KDNY
81
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4.04M 0.11%
110,000
– –
2016 Q3
8 quarters
LJPC
82
DELISTED
La Jolla Pharmaceutical Company
LJPC
$4.03M 0.1%
200,000
-50,000
-20% -$1.31M
2018 Q1
2 quarters
YMAB icon
83
DELISTED
Y-mAbs Therapeutics
YMAB
$3.98M 0.1%
+150,000
New +$3.81M
2018 Q3
0 quarters
CMRX icon
84
DELISTED
Chimerix, Inc.
CMRX
$3.89M 0.1%
1,000,000
+500,000
+100% +$2.13M
2016 Q3
8 quarters
ELAN icon
85
Elanco Animal Health
ELAN
$11.5B
$3.49M 0.09%
+100,000
New +$3.52M
2018 Q3
0 quarters
XENE icon
86
Xenon Pharmaceuticals
XENE
$3.53B
$3.3M 0.09%
250,000
+100,000
+67% +$1.16M
2017 Q1
6 quarters
FLEX icon
87
Flex
FLEX
$44.3B
$3.28M 0.09%
+331,750
New +$3.47M
2018 Q3
0 quarters
TCDA
88
DELISTED
Tricida, Inc. Common Stock
TCDA
$3.06M 0.08%
100,000
– –
2018 Q2
1 quarter
HSTO
89
DELISTED
Histogen Inc. Common Stock
HSTO
$2.9M 0.08%
+2,500
New +$2.3M
2018 Q3
0 quarters
GRTS icon
90
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$2.85M 0.07%
+200,000
New +$2.85M
2018 Q3
0 quarters
SYBX icon
91
DELISTED
Synlogic
SYBX
$2.84M 0.07%
13,333
-13,334
-50% -$2.11M
2017 Q4
3 quarters
VRDN icon
92
Viridian Therapeutics
VRDN
$2.11B
$2.79M 0.07%
33,333
– –
2017 Q3
4 quarters
KRYS icon
93
Krystal Biotech
KRYS
$9.82B
$2.64M 0.07%
150,000
– –
2017 Q3
4 quarters
NTLA icon
94
Intellia Therapeutics
NTLA
$1.83B
$2.58M 0.07%
90,000
– –
2016 Q2
9 quarters
ADVM icon
95
DELISTED
Adverum Biotechnologies
ADVM
$2.42M 0.06%
40,000
– –
2018 Q1
2 quarters
DNTH icon
96
Dianthus Therapeutics
DNTH
$4.61B
$2.4M 0.06%
12,500
– –
2018 Q2
1 quarter
QTTB icon
97
Q32 Bio
QTTB
$248M
$2.29M 0.06%
5,556
– –
2018 Q1
2 quarters
TGTX icon
98
TG Therapeutics
TGTX
$8.48B
$2.24M 0.06%
400,000
– –
2017 Q2
5 quarters
IRWD icon
99
Ironwood Pharmaceuticals
IRWD
$631M
$2.04M 0.05%
131,975
-126,979
-49% -$2.01M
2013 Q2
21 quarters
NVAX icon
100
Novavax
NVAX
$2.1B
$940K 0.02%
25,000
– –
2016 Q3
8 quarters
1 2 3
4
5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
ACM
Ashe Capital Management Englewood Cliffs, New Jersey $931M AUM 4.95% 1-Year Est. Return
SAM
Sycomore Asset Management Paris, France $932M AUM 51.25% 1-Year Est. Return
NS
Night Squared New York $930M AUM 56.46% 1-Year Est. Return
PA
Planning Alternatives Birmingham, Michigan $933M AUM 28.32% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $933M AUM 56.2% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $929M AUM 53.07% 1-Year Est. Return
CAM
Claret Asset Management Montreal, Quebec, Canada $928M AUM 25.4% 1-Year Est. Return

Artal Group's Q3 2018 Portfolio in Review

As of Q3 2018, Artal Group held 122 positions worth $3.84B, down 18% from $4.71B the previous quarter. Its ten largest holdings account for 67% of the portfolio.

Artal Group withdrew a net $395M in Q3 2018, closing 17 positions and reducing 23 holdings. Its most notable exit was Global Blood Therapeutics, Inc., an estimated $9.04M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 46% of assets, up from 37% a quarter earlier, followed by Consumer Discretionary and Miscellaneous.

Against the trend, Artal Group opened a new position in Rubius Therapeutics, Inc worth $69.8M.

  • Artal Group's largest Q3 2018 buy was Rubius Therapeutics, Inc: 2,908,791 shares worth $69.8M.
  • Artal Group added most to Amicus Therapeutics in Q3 2018, an estimated $15.4M increase.
  • Artal Group's biggest Q3 2018 reduction was WW International, cutting an estimated $487M.
  • Artal Group fully exited Global Blood Therapeutics, Inc. in Q3 2018, selling an estimated $9.04M.
  • Artal Group's ten largest holdings make up 67% of its $3.84B portfolio in Q3 2018.
  • Artal Group opened 18 new positions and closed 17 in Q3 2018.
  • Artal Group's portfolio value fell 18% quarter-over-quarter to $3.84B.

Based on Artal Group's 13F filing for Q3 2018, filed 9 Nov 2018.